A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers
Status:
Completed
Trial end date:
2015-10-28
Target enrollment:
Participant gender:
Summary
This study will be conducted in a single centre, as an open single dose two parallel cohorts
design with oral doses of MMV390048 administered in healthy male and female subjects between
18 to 55 years of age. Subjects will be screened within 28 days prior to entering the study.
On Day 1 of the study each subject will receive one of the two MMV390048 prototype
formulations, at a dose of 40 mg with 240 mL of water. Subjects will be discharged on Day 3
after 48h post-dose and they will attend the unit for follow-up visits on Days 5, 7, 10, 14,
19, 26 and 29.